The USPTO can refuse a CBD or cannabis trademark application for two broad reasons: the underlying goods or services may not qualify as lawful federal commerce, or the application may fail an ordinary trademark requirement such as likelihood of confusion, distinctiveness, ownership, or an acceptable specimen.
This distinction is important because receiving a state cannabis license does not automatically make a trademark federally registrable. Likewise, identifying a product as “hemp-derived” does not resolve every federal-law issue.
For CBD and cannabis businesses, a USPTO refusal may therefore require analysis of both trademark law and the federal statutes governing the actual product or service.
As of August 31, 2026, the federal treatment of marijuana has also become more complicated. A rule effective April 28, 2026 created limited Schedule III treatment for certain FDA-approved marijuana drug products and certain medical marijuana subject to state licensing and the applicable federal registration framework. It did not broadly move all recreational marijuana or every cannabis business into Schedule III.
What Are the Most Common Reasons a CBD or Cannabis Trademark Is Refused?
CBD and cannabis applications may encounter lawful-use refusals under Sections 1 and 45 of the Trademark Act, FDA-related objections involving CBD foods, dietary supplements, or drugs, Controlled Substances Act issues, overbroad or inaccurate identifications of goods, specimen refusals, likelihood-of-confusion refusals under Section 2(d), descriptiveness refusals under Section 2(e)(1), or applicant-ownership problems.
The reason matters because these refusals are not interchangeable.
A likelihood-of-confusion refusal may call for arguments about the marks and goods. A specimen refusal may sometimes be addressed with qualifying evidence of actual use. A lawful-use refusal involving goods that cannot legally enter federal commerce can present a much more fundamental obstacle.
Why Does the USPTO Require Lawful Use in Commerce?
Federal trademark registration generally requires lawful use in commerce or a bona fide intention to make lawful use in commerce.
TMEP §907 explains that use of a mark must be lawful to support federal registration. The goods or services associated with the mark must comply with applicable federal laws.
The USPTO does not ordinarily conduct a complete regulatory investigation of every applicant. Under TMEP §907, the Office generally presumes that an applicant’s use is lawful unless the application record indicates otherwise.
A lawful-use problem can arise, however, when the record indicates a violation of federal law or the applicant’s relevant activity constitutes a per se violation of federal law.
Evidence can come from the identification of goods and services, the specimen, the applicant’s website, product descriptions, regulatory findings, or other information contained in the record.
That is particularly significant for CBD and cannabis companies because their own product pages and packaging may provide the examining attorney with information about ingredients, cannabinoid content, intended use, or medical claims.
Does a State Cannabis License Make a Trademark Federally Registrable?
No. State authorization by itself does not establish eligibility for federal trademark registration.
TMEP §907 has long recognized that activity permitted under state law can still fail the federal lawful-use requirement when the relevant commercial activity violates federal law.
The federal treatment of medical marijuana changed significantly in April 2026, but those changes do not mean that every state-licensed cannabis company automatically qualifies for federal trademark protection.
Effective April 28, 2026, the Department of Justice issued a final rule placing certain FDA-approved drug products containing marijuana and marijuana subject to qualifying state medical-marijuana licenses within Schedule III. The rule also established federal registration requirements for entities handling covered medical marijuana.
Importantly, the rule states that forms of marijuana outside the FDA-approved and covered state medical-marijuana categories remain Schedule I unless another federal rule changes their status.
A company operating under a state recreational cannabis license should therefore not assume that the April 2026 rule makes its underlying activity federally lawful.
Was Marijuana Federally Rescheduled to Schedule III in 2026?
Only in limited circumstances.
This is an area where CBD and cannabis businesses should be precise.
The April 28, 2026 final rule created Schedule III treatment for specified FDA-approved marijuana drug products and marijuana covered by qualifying state medical-marijuana licensing, subject to the rule’s federal regulatory requirements.
A separate proceeding addresses the broader proposal to transfer marijuana from Schedule I to Schedule III. DEA conducted formal hearings on that broader proposal during the summer of 2026.
As of August 31, 2026, businesses should not treat that broader proposed rescheduling as though it were already a final rule applicable to all marijuana products and businesses.
This distinction can be especially important in a trademark application because the USPTO analyzes the goods and services actually identified in the application, not cannabis regulation in the abstract.
Can a Hemp-Derived CBD Trademark Still Be Refused?
Yes.
The fact that CBD comes from qualifying hemp does not automatically make every CBD product lawful for federal trademark purposes.
Under the federal hemp definition currently applicable through November 11, 2026, qualifying hemp generally includes Cannabis sativa L. and its derivatives containing no more than 0.3 percent delta-9 THC on a dry-weight basis.
Removing qualifying hemp from the Controlled Substances Act definition of marijuana resolved one federal issue. It did not eliminate regulation under the Federal Food, Drug, and Cosmetic Act.
TMEP §907 expressly recognizes that products containing hemp extracts may remain unlawful under other federal statutes.
That distinction is one of the most important reasons hemp-derived CBD trademark applications continue to receive refusals.
Why Does the USPTO Refuse Trademarks for CBD Foods and Gummies?
CBD foods may encounter a lawful-use refusal because of the FDA’s current interpretation of the Federal Food, Drug, and Cosmetic Act.
The FDA continues to state that introducing food into interstate commerce with added CBD is prohibited under Section 301(ll) of the FDCA, subject to statutory exceptions that the agency has not found applicable to ordinary CBD food products.
As a result, products such as CBD gummies, CBD-infused beverages, candies, pet foods, and similar ingestible products can create federal trademark problems even when their CBD is derived from hemp.
For example, changing an identification from “CBD gummies” to “hemp-derived gummies containing no more than 0.3% delta-9 THC” does not necessarily solve the issue. The THC limitation addresses the federal definition of hemp, but it does not resolve the separate FDA restriction concerning the addition of CBD to food.
A trademark application must account for every applicable federal statute, not merely the Controlled Substances Act.
Why Are CBD Dietary Supplement Trademarks Frequently Refused?
CBD dietary supplements present a similar issue.
The FDA’s current position is that CBD is excluded from the statutory definition of a dietary supplement under Section 201(ff)(3)(B) of the FDCA.
According to the FDA, CBD was the subject of substantial clinical investigations and is an active ingredient in an approved drug. The FDA has not issued a regulation that would presently permit CBD to be marketed as a conventional dietary supplement notwithstanding that exclusion.
Consequently, describing a product as a “hemp-derived CBD dietary supplement” may still lead to a lawful-use refusal.
This is another example of why satisfying the federal hemp definition does not automatically establish that the commercial use supporting a trademark application is lawful.
Can Therapeutic Claims Cause a CBD Trademark Refusal?
Yes. The way a CBD product is marketed can change its regulatory status.
A topical CBD cream might initially appear less problematic than a CBD gummy or dietary supplement. But the analysis can change if the company markets the product as relieving pain, treating inflammation, reducing anxiety, treating arthritis, healing eczema, improving a disease, or producing another therapeutic effect.
Under the FDCA, products intended to diagnose, cure, mitigate, treat, or prevent disease, or intended to affect the structure or function of the body, can fall within the definition of a drug.
An unapproved new drug generally cannot be introduced into interstate commerce.
This means the USPTO may look beyond the words appearing in the identification of goods.
Product packaging, website descriptions, advertising, social media, and even the language appearing on the submitted specimen can reveal an intended therapeutic use that creates a federal-law problem.
Has the TTAB Refused a Hemp-Derived CBD Topical Trademark?
Yes.
A useful example is In re CBH International, LLC, Serial No. 88979768 (TTAB Jan. 3, 2024), a nonprecedential Trademark Trial and Appeal Board decision.
The applicant sought registration for “topical analgesics” and “analgesic balms” containing ingredients naturally occurring in industrial hemp with no more than 0.3 percent delta-9 THC on a dry-weight basis.
The Board nevertheless affirmed the refusal.
The problem was not simply the THC concentration. The identified products were analgesics, and the record showed that they contained CBD and were intended to relieve pain. The Board concluded that the goods were drugs under the Federal Food, Drug, and Cosmetic Act and that there was no evidence of the required FDA approval.
The case illustrates an important principle for CBD trademark applicants: a hemp limitation can address a Controlled Substances Act issue while leaving a separate FDA problem unresolved.
Can the Identification of Goods Cause a CBD Trademark Refusal?
Yes. An inaccurate, indefinite, or overly broad identification can create problems that a more carefully drafted application might have avoided.
Terms such as “cannabis products,” “CBD products,” or “hemp products” may be too vague to identify precisely what the applicant sells. They can also encompass goods subject to different federal regulatory regimes.
A broad identification may include lawful and unlawful products within the same wording.
For example, a company may actually sell only a non-medicated hemp-derived cosmetic but file an application broadly covering CBD skincare products, medicated preparations, dietary supplements, and other cannabinoid products.
That unnecessarily introduces additional legal questions.
The identification should describe the company’s actual lawful goods or services with enough precision to permit proper examination.
Is Adding a 0.3 Percent THC Limitation Enough?
Not necessarily.
USPTO cannabis guidance issued after the 2018 Farm Bill historically instructed applicants seeking registration for qualifying hemp-derived goods to include appropriate language limiting the goods according to the federal hemp definition.
That limitation can be important, but it does not cure unrelated federal-law problems.
A dietary supplement can contain hemp-derived CBD with no more than the applicable THC threshold and still face an FDCA issue. The same is true of a hemp-derived CBD analgesic marketed as a drug.
Applicants should therefore avoid treating the THC limitation as universal language that automatically makes a cannabis-related identification registrable.
The relevant question is whether the complete commercial activity described in the application is lawful under all applicable federal laws.
Is the Federal Hemp Definition Changing in November 2026?
Yes.
A significant amendment to the federal definition of hemp is scheduled to take effect on November 12, 2026.
The amended framework changes the analysis from the existing delta-9 THC standard to a total-THC approach that includes tetrahydrocannabinolic acid. It also contains exclusions affecting certain intermediate and final hemp-derived cannabinoid products, including specified synthesized cannabinoids and cannabinoid concentration limits.
This change can be especially important for intent-to-use applications filed before November 12, 2026 but relying on commercial use occurring after the new definition becomes effective.
A CBD or hemp business should therefore evaluate not only whether its products satisfy the law on the application filing date, but also whether the intended products can lawfully be offered when evidence of use will later be submitted.
Can Filing an Intent-to-Use Application Avoid a Lawful-Use Refusal?
No.
An intent-to-use application under Section 1(b) allows a business to file before it has begun using the trademark in commerce. It does not permit the applicant to claim an intention to engage in activity that cannot lawfully occur.
TMEP §907 provides that when the identified goods or services are unlawful, actual lawful use is not possible. A refusal may therefore be appropriate because the applicant cannot possess the required bona fide intent to lawfully use the mark in commerce for those goods or services.
This point was also central in In re CBH International, LLC. The application was filed on an intent-to-use basis, but the Board concluded that the applicant lacked the required bona fide intent to make lawful use because the identified CBD analgesic products could not lawfully be introduced into commerce without the applicable FDA approval.
Filing before launch therefore does not eliminate the need for regulatory analysis.
Can a Trademark Specimen Cause a CBD or Cannabis Application to Be Refused?
Yes. Specimens can create both ordinary trademark problems and cannabis-specific problems.
For goods, a specimen must generally show the mark used on the goods, packaging, labels, containers, or an acceptable display associated with the goods.
The USPTO may refuse specimens that are digitally created mockups, altered images, advertisements that do not qualify as specimens for goods, pictures showing only the trademark, or webpages lacking an adequate purchasing mechanism.
A CBD or cannabis applicant has an additional risk.
The specimen may contradict statements made elsewhere in the application.
For example, an application might identify a “non-medicated hemp-derived topical cosmetic,” while the submitted packaging says that the product provides “fast arthritis pain relief.”
The trademark specimen has then revealed evidence relevant to the product’s intended use.
Before filing a specimen, CBD applicants should review not only whether it technically shows trademark use, but also what the specimen says about the nature and regulatory status of the underlying product.
Can the USPTO Look at a CBD Company’s Website?
Potentially, yes.
The USPTO’s lawful-use analysis is not necessarily limited to the four corners of the identification.
TMEP §907 permits examining attorneys to require additional information about goods or services when needed to determine compliance with federal law. Existing TTAB decisions also demonstrate that evidence concerning how products are actually marketed may become part of the examination record.
A website describing a CBD product as an anxiety treatment, pain reliever, sleep medication, or medical-grade therapeutic product can therefore create issues even if the formal identification uses more neutral language.
For CBD and cannabis companies, application strategy should be consistent with the actual product, website, labeling, and advertising.
Can a CBD Trademark Be Refused for Likelihood of Confusion?
Yes.
A CBD or cannabis application that satisfies federal lawful-use requirements is still subject to the same trademark examination standards as other applications.
Under Section 2(d) of the Trademark Act, the USPTO may refuse registration when the proposed mark is sufficiently similar to an earlier registered mark and the respective goods or services are sufficiently related that consumers are likely to be confused about source, sponsorship, or affiliation.
The marks do not need to be identical.
For a CBD wellness brand, potentially relevant prior registrations might cover cosmetics, skincare, pharmaceuticals, wellness products, hemp goods, supplements, retail services, or related categories, depending on the facts.
A comprehensive trademark search should therefore take place before the company invests substantially in packaging, website development, product manufacturing, or advertising.
Can a CBD Trademark Be Refused as Merely Descriptive?
Yes.
Section 2(e)(1) of the Trademark Act permits the USPTO to refuse a mark that is merely descriptive of the applicant’s goods or services.
A term can be descriptive when it immediately communicates an ingredient, purpose, characteristic, quality, function, or use of the product.
CBD businesses frequently build names around terms such as “CBD,” “hemp,” “relief,” “wellness,” “natural,” “organic,” “calm,” “therapeutic,” or similar wording.
Whether the complete mark is descriptive depends on the mark and the identified goods, but businesses relying heavily on descriptive terminology may encounter both registration problems and a narrower scope of protection.
A distinctive or invented brand name generally provides a stronger foundation for trademark protection.
Can Filing Under the Wrong Company Cause a CBD Trademark Application to Fail?
Yes, and ownership mistakes can be particularly serious.
Under TMEP §1201.02(b), an application must be filed by the party that owns the mark, or in an intent-to-use application, the party possessing the bona fide intention to use the mark, on the application filing date.
If the application is filed in the name of the wrong party, the defect generally cannot simply be cured by assigning the application to the correct company.
This problem can be especially easy to create in the cannabis industry because businesses may operate through several related entities.
One company may own intellectual property while another handles manufacturing. A different entity may hold a state cannabis license, distribute products, operate a dispensary, or employ the company’s personnel.
The correct trademark owner should be determined before the application is filed.
What Should a CBD or Cannabis Company Do After Receiving a USPTO Office Action?
The first step is to determine exactly what type of refusal or requirement the examining attorney issued.
A lawful-use refusal should not automatically be treated like an ordinary trademark objection. The business may need to examine product formulation, licensing, FDA status, cannabinoid content, intended use, website claims, packaging, and the exact identification of goods.
A Section 2(d) refusal requires a different analysis focused primarily on the applied-for mark, cited registrations, and the relationship between the respective goods or services.
A specimen refusal may require review of how and when the mark was actually used.
An ownership problem can raise still different questions, particularly when the wrong legal entity filed the original application.
The Office Action should therefore be analyzed issue by issue before deciding whether amendment, legal argument, additional evidence, or another filing strategy is appropriate.
Can Every CBD or Cannabis Trademark Refusal Be Fixed?
No.
Some Office Actions identify defects that can potentially be corrected. Others expose a fundamental problem with the application.
For example, an indefinite identification may sometimes be amended. Certain specimen problems may sometimes be overcome with an acceptable substitute specimen that satisfies the applicable filing-date requirements.
By contrast, if the underlying goods could not lawfully be offered in federal commerce and the application lacks a valid basis for registration, changing a few words in the identification may not solve the underlying problem.
Similarly, an application filed by a genuinely incorrect owner may be void rather than merely defective.
The distinction between a curable examination issue and a fundamental filing problem is therefore one of the most important questions to answer after receiving an Office Action.
How Can CBD and Cannabis Companies Reduce the Risk of a USPTO Refusal?
The best time to evaluate these issues is before filing.
A business should first determine exactly what it sells or intends to sell and which legal entity owns the trademark. It should review the product’s ingredients, cannabinoid content, intended purpose, regulatory classification, marketing claims, labeling, website language, and sales model.
It should then conduct a comprehensive trademark clearance search and prepare an identification that accurately reflects the goods or services the business can genuinely and lawfully provide.
If the application will rely on existing use, the proposed specimen should also be reviewed before submission.
For filings made during 2026, companies should pay particular attention to the April 2026 marijuana developments and the federal hemp-definition changes scheduled to take effect on November 12, 2026.
Frequently Asked Questions About CBD and Cannabis Trademark Refusals
Why did the USPTO refuse my CBD trademark?
Common reasons include unlawful federal commerce, an FDA issue involving CBD foods, supplements, or drugs, an improper specimen, an overly broad identification, likelihood of confusion, descriptiveness, or an ownership problem.
Does hemp-derived CBD automatically qualify for a federal trademark?
No. Compliance with the federal hemp definition addresses only part of the analysis. The product may still be regulated under the Federal Food, Drug, and Cosmetic Act or another federal statute.
Can CBD gummies receive federal trademark registration?
CBD gummies can present a significant lawful-use problem because the FDA currently maintains that introducing food with added CBD into interstate commerce is prohibited under the FDCA.
Can a CBD topical product receive a federal trademark?
Potentially. A non-medicated cosmetic containing qualifying hemp-derived CBD may present a different regulatory analysis from an ingestible CBD product. Therapeutic or disease-treatment claims, however, can cause a topical product to be regulated as a drug.
Can I file an intent-to-use CBD trademark before launching the product?
Potentially, but the applicant must possess a bona fide intention to make lawful use of the mark. An intent-to-use filing does not cure a situation in which the identified goods cannot lawfully be offered in commerce.
Did marijuana become Schedule III in 2026?
Certain FDA-approved marijuana drug products and marijuana within specified state medical-marijuana licensing categories became subject to Schedule III treatment under an April 28, 2026 final rule and related federal registration requirements. That should not be confused with the separate broader marijuana-rescheduling proceeding.
Can a state-licensed marijuana dispensary automatically obtain a federal trademark?
No. State licensing alone does not automatically establish eligibility for federal trademark registration. The particular goods or services and their status under federal law still need to be evaluated.
Can the USPTO review my website when examining a cannabis trademark?
Yes, information concerning the applicant’s actual goods, services, or commercial activity can become relevant when the record raises questions about lawful use. Website claims may be particularly important when they reveal CBD content or therapeutic intended use.
Can an unacceptable specimen be replaced?
Sometimes. Whether a substitute specimen can resolve the refusal depends on the filing basis, when the substitute specimen was in actual use, and the reason the original specimen was unacceptable.
What happens if the wrong company filed the trademark application?
An application filed by the wrong party can be void. TMEP §1201.02(b) distinguishes between certain correctable errors in identifying an otherwise proper applicant and an application genuinely filed by a party that did not own or possess the required intent to use the mark.
Final Thoughts
Why does the USPTO refuse CBD and cannabis trademark applications?
The answer is often more complicated than an ordinary trademark examination because the USPTO may need to consider both trademark law and the federal legality of the underlying commercial activity.
A hemp-derived product can still encounter an FDA problem. A state-licensed cannabis company may still face federal limitations. A legally permissible product can still be refused because of an earlier trademark, descriptive wording, an unacceptable specimen, or the wrong applicant.
The rapidly changing federal treatment of marijuana and hemp makes filing strategy especially important in 2026.
CBD and cannabis businesses should therefore review federal regulatory eligibility, trademark availability, ownership, identification language, marketing claims, and specimen evidence as connected parts of the application process rather than treating each issue separately.
Primary Authorities and Sources
The principal authorities relevant to these issues include Trademark Act Sections 1, 2(d), 2(e), and 45; 15 U.S.C. §§1051, 1052, and 1127; TMEP §907 concerning compliance with other federal statutes; TMEP §904 concerning specimens; TMEP §1201.02 concerning ownership and identification of the applicant; USPTO Examination Guide 1-19 concerning cannabis and cannabis-related goods after the 2018 Farm Bill; the Controlled Substances Act; the Federal Food, Drug, and Cosmetic Act; FDA guidance concerning cannabis and cannabis-derived products; the Department of Justice’s April 28, 2026 marijuana rules; and relevant TTAB decisions including In re CBH International, LLC, Serial No. 88979768 (TTAB Jan. 3, 2024).
Author: Abraham Cohn, Founder, Cohn Legal, PLLC. Abraham Cohn is a U.S. trademark attorney who advises businesses on trademark clearance, federal trademark registration, USPTO Office Actions, brand protection, and trademark disputes.